Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27993120 | 0.80 | DDR1 (0.36) | CCR2MAPTPOLBSMN1; SMN2TRPV4 | |
| SCHEMBL2169120 | 0.79 | CA1 (0.40) | MAPTPTGS2 | |
| SCHEMBL5502033 | 0.79 | TSHR (0.32) | MAPTS100A4LMNAKIF18A | |
| SCHEMBL2168627 | 0.77 | CA1 (0.34) | MAPTPTGS2LMNA | |
| SCHEMBL941266 | 0.77 | G6PD (0.37) | MAPTSMN1; SMN2PTGS2LMNA | |
| SCHEMBL5868198 | 0.75 | L3MBTL1 (0.42) | LMNA | |
| SCHEMBL28023854 | 0.75 | — | — | |
| SCHEMBL1116610 | 0.75 | PTGS2 (0.38) | PTGS2 | |
| SCHEMBL2168568 | 0.75 | SLC22A12 (0.33) | S100A4 | |
| SCHEMBL5868210 | 0.73 | PTGS2 (0.41) | MAPTSMN1; SMN2PTGS2S100A4AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699028-A | It is substituted 4- phenylpyridine compounds as non-systemic TGR5 agonists | 阿德利克斯公司 | 2018-10-23 | — | — | CN | claimed |
| CN-108290871-A | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2018-07-17 | — | — | CN | claimed |
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2280966-A1 | AZABICYCLO [3.2.1]OCTYL DERIVATIVES AS 11 BETA-HSD1 MODULATORS | Exelixis, Inc. (US) | 2011-02-09 | — | — | EP | claimed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | claimed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| WO-2009114173-A1 | AZABICYCLO [3. 2. I] OCTYL DERIVATIVES AS 11 BETA-HSDL MODULATORS | EXELIXIS, INC. (US) | 2009-09-17 | — | — | WO | claimed |
| EP-1809600-A4 | CYCLIC B-AMINO ACID DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | claimed |
| EP-1667647-A4 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1670739-A4 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006041831-A2 | CYCLIC Β-AMINO ACID DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-20 | — | — | WO | claimed |
| US-20060074103-A1 | Cyclic beta-amino acid derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-06 | — | — | US | claimed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | claimed |
| US-20050085511-A1 | Cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-21 | — | — | US | claimed |
| WO-2005032490-A2 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1505966-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | claimed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | CCR2 3450/4885MAPT 3067/4885POLB 2249/4885 |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | CCR2 1294/4885MAPT 4263/4885POLB 3904/4885 |
| US-20060074103-A1 | Cyclic beta-amino acid derivatives as factor Xa inhibitors | SERPINC1, PEPD, F11 | CCR2 2529/4885MAPT 4394/4885POLB 3058/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | CCR2 2219/4885MAPT 4606/4885POLB 2045/4885 |
| US-20050085511-A1 | Cyclic diamines and derivatives as factor Xa inhibitors | TFPI, SERPINC1, F12 | CCR2 2629/4885MAPT 4553/4885POLB 2071/4885 |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | HSD11B1, HSD11B2, HSD3B1 | CCR2 3886/4885MAPT 3414/4885POLB 2040/4885 |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | CCR2 2022/4885MAPT 4614/4885POLB 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.